Generic Injectables Market Worth $150.65Bn, Globally, by 2028 at 10.5% CAGR - Exclusive Report by The Insight Partners
March 25, 2022 06:22 ET
|
The Insight Partners
New York, March 25, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Generic Injectables Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product...
Inhalation & Nasal Spray Generic Drugs Market at CAGR of 8.29% by 2031: Visiongain Research Inc.
June 17, 2021 12:30 ET
|
Visiongain Ltd
Visiongain has published a new report on Inhalation & Nasal Spray Generic Drugs Market Report 2021-2031. Profiles of Inhalation & Nasal Spray Generic Drugs and Forecasts By Drug Class...
Generic Oncology Drugs Market Growth Sturdy at 6.3% CAGR to Outstrip $36,029.60 Million by 2027 - COVID-19 Impact and Global Analysis by TheInsightPartners.com
June 16, 2021 08:10 ET
|
The Insight Partners
Pune, India., June 16, 2021 (GLOBE NEWSWIRE) -- Generic Oncology Drugs Market: Key InsightsAccording to our new research study on “Generic Oncology Drugs Market to 2027 – Global Analysis and...
Saudi Arabia Pharmaceutical Drugs Market to Surpass US$ 16,663.1 Million by 2027, Says Coherent Market Insights (CMI)
April 23, 2021 08:30 ET
|
CMI
SEATTLE, April 23, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the Saudi Arabia pharmaceutical drugs market is estimated to be valued at US$ 10,191.4 million in 2020 and is...
Generic Drugs Market Value Predicted To Reach US$ 627.6 Billion By 2027: Acumen Research And Consulting
April 01, 2021 12:15 ET
|
Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Generic Drugs Market – Global Industry Analysis, Market Size, Opportunities and...
Celgene Rescinds Agreement to Compensate Cancer Patients Days Before Christmas
January 08, 2020 13:36 ET
|
Hausfeld
WASHINGTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- On December 23, 2019, Celgene backed out of a settlement in which it had agreed to pay $55 million to end payors (consumers, insurers, union health and...
Elite Pharmaceuticals Enters into Strategic Marketing Alliance with Lannett For Generic Adderall®
March 11, 2019 06:45 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 11, 2019 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) announced today that it has entered into a license, supply, and distribution...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2019 Ended December 31, 2018 and Provides Conference Call Information
February 11, 2019 17:34 ET
|
Elite Pharmaceuticals, Inc.
Conference Call Scheduled for Tuesday, February 12th at 11:30 AM EST NORTHVALE, N.J., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2019 Financial Results on February 12, 2019
February 07, 2019 06:00 ET
|
Elite Pharmaceuticals, Inc.
Northvale, NJ, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB: ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
SunGen Pharma Receives Its Second and Third ANDA Approval from US FDA
December 11, 2018 07:30 ET
|
SunGen Pharma LLC
PRINCETON, N.J., Dec. 11, 2018 (GLOBE NEWSWIRE) -- SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products,...